title: [Immunosuppression may mask severe infection. Septic arthritis in tocilizumab treatment yielded only modest acute-phase reaction].
authors.affiliation: Institutionen för folkhälsa och klinisk medicin, Umeå universitet. lotta.ljung@vll.se
authors.forename: Lotta
authors.initials: L
authors.lastname: Ljung
authors.forename: Johan
authors.initials: J
authors.lastname: Smeds
authors.forename: Gunilla
authors.initials: G
authors.lastname: Persson
authors.forename: Lena
authors.initials: L
authors.lastname: Jirlén
authors.forename: Göran
authors.initials: G
authors.lastname: Toolanen
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001170:Arthritis, Infectious / Q000175:diagnosis*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D002097:C-Reactive Protein / Q000032:analysis; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors; D012307:Risk Factors; D013211:Staphylococcus aureus / Q000302:isolation & purification
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents; D019947:Receptors, Interleukin-6; D002097:C-Reactive Protein; C502936:tocilizumab